|
Jun 23
|
High Growth Tech Stocks To Watch In June 2025
|
|
Jun 20
|
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
|
|
Jun 18
|
High Growth Tech Stocks in Europe for June 2025
|
|
Jun 18
|
High Growth Tech Stocks In Europe To Watch
|
|
Apr 15
|
Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?
|
|
Apr 14
|
Is Argenx SE (ARGX) the Best Growth Stock to Buy According to Billionaires?
|
|
Jan 1
|
Exploring High Growth Tech Stocks for January 2025
|
|
Oct 9
|
argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ...
|
|
Oct 7
|
Zacks.com featured highlights include Argenx SE Alphatec and Olin
|
|
Sep 25
|
Amgen stock falls on lackluster drug data
|
|
Sep 25
|
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
|
|
Jul 25
|
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
|
|
Jun 25
|
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
|
|
Jun 25
|
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
|
|
Jun 24
|
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
|
|
Jun 24
|
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
|
|
Jun 24
|
FDA approves argenx’s VYVGART Hytrulo for CIDP treatment
|
|
Jun 21
|
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
|
|
Jan 12
|
How Argenx (ARGX) Stock Stands Out in a Strong Industry
|
|
Jan 2
|
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
|